Candidate Compounds Covid19

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(95 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
{{pnc}}
+
{{gohome}}
 +
{{ft|P}}
 +
  '''CHERRYPICKING STUDIES IS NOT SCIENCE
 +
{{qt|Reviews on covid drug development}}
  
'''reviews & screen candidate compounds covid19'''
 
{{tp|p=32226821|t=2020. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases |pdf=|usr=}}
 
{{tp|p=32292689|t=ä. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods |pdf=|usr=}}
 
{{tp|p=32318328|t=ä. D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19 |pdf=|usr=}}
 
{{tp|p=32152082|t=2020. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus |pdf=|usr=}}
 
{{tp|p=32232214|t=2020. Potential Treatments for COVID-19; a Narrative Literature Review |pdf=|usr=}}
 
{{tp|p=32134278|t=2020. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) |pdf=|usr=}}
 
{{tp|p=32375268|t=2020. Coronavirus Pandemic-Therapy and Vaccines |pdf=|usr=}}
 
{{tp|p=31996494|t=2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV) |pdf=|usr=}}
 
{{tp|p=32334062|t=ä. Current status of potential therapeutic candidates for the COVID-19 crisis |pdf=|usr=}}
 
{{tp|p=32347359|t=ä. Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19 |pdf=|usr=}}
 
{{tp|p=32162456|t=2020. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep  Docking of 1 3 Billion Compounds |pdf=|usr=}}
 
{{tp|p=32194980|t=2020. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32149769|t=ä. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model |pdf=|usr=}}
 
  
 +
*'''[[scouting ideas]]'''
  
'''Icatibant''' bradykinin antagonist
+
*'''[[PHA Biologicals]]'''
{{tp|p=32359101|t=2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications |pdf=|usr=}}
+
  
'''Arbidol''' retarget influenza
+
*'''[[PHA conventional pharmacology]]'''
{{tp|p=32373347|t=2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro |pdf=|usr=}}
+
  
'''Macrolide antibiotics'''
+
*'''[[PHA retargeted compounds]]'''
{{tp|p=32249257|t=2020. Macrolide treatment for COVID-19: Will this be the way forward?|pdf=|usr=}}
+
  
'''Oleoylethanolamide'''
+
*'''[[PHA antivirals by mechanism]]'''
{{tp|p=32327293|t=ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19 |pdf=|usr=}}
+
  
'''Metronidazole''' retarget
+
*'''[[PHA pharmacophore by screened target]]'''
{{tp|p=32259129|t=2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen |pdf=|usr=}}
+
  
'''Glutathione GSH''' antioxidant
+
*'''[[PHA ImmunoNutrients]]
*[https://nypost.com/2020/05/09/new-york-mom-with-coronavirus-saved-by-medical-student-son/ found in a forrest gump mode]
+
*[https://www.sciencedirect.com/science/article/pii/S2213007120301350 Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases]
+
  
'''Chlorpromazine''' retarget
+
*'''[[PHA compl altern natural]]'''
*[https://www.biorxiv.org/content/10.1101/2020.05.05.079608v1 paper]
+
  
'''Zinc''' add-on
+
*'''[[PHA within indications compounds]]'''
*[https://www.sciencedirect.com/science/article/pii/S0306987720306435 call for trial]
+
  
'''Selenium'''
+
*'''[[PHA Serum products]]'''
{{tp|p=32342979|t=ä. Association between regional selenium status and reported outcome of COVID-19 cases in China |pdf=|usr=}}
+
  
'''Remdesivir''' retarget
+
*'''[[PHA Vaccination]]'''
*[https://gab.com/Remnant601/posts/104122987152232660 one hospital on...]
+
{{tp|p=32283108|t=ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites |pdf=|usr=}}
+
{{tp|p=32020029|t=2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro |pdf=|usr=}}
+
  
'''Lauric acid''' nat. compd.
+
PHA related options:
*[https://www.icp.org.ph/2020/01/the-potential-of-coconut-oil-and-its-derivatives-as-effective-and-safe-antiviral-agents-against-the-novel-coronavirus-ncov-2019/ call for trial]
+
  
'''Nicotine''' nat. toxin
+
*[[Radiation therapy]]
*[https://www.usatoday.com/story/news/factcheck/2020/05/03/covid-19-fact-check-caution-urged-study-virus-smoking/3055378001/ france]
+
*[[Phototherapy]]
 +
*[[Electric fields]]
 +
*[[Treatment other concepts]]
  
'''Niclosamide'''
 
{{tp|p=32125140|t=ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential |pdf=|usr=}}
 
  
'''Microbiome as target'''
+
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
{{tp|p=32356654|t=ä. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles |pdf=|usr=}}
+
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
 +
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
 +
Paper is (not yet in PubMed) :
  
'''ACE2 as target'''
+
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
{{tp|p=32286790|t=ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 |pdf=|usr=}}
+
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
{{tp|p=32333836|t=ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 |pdf=|usr=}}
+
based on e.g.
  
 +
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
  
'''Garlic extracts'''
+
=======================================================================================
{{tp|p=32363255|t=ä. Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil |pdf=|usr=}}
+
  
'''Dipyridamole''' retarget
+
COVID19 is now a CURABLE disease !!!
{{tp|p=32318327|t=ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 |pdf=|usr=}}
+
  
'''stem cells'''
+
  =======================================================================================
{{tp|p=32257554|t=2020. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia |pdf=|usr=}}
+
{{tp|p=32257537|t=2020. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia |pdf=|usr=}}
+
{{tp|p=32283815|t=2020. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use |pdf=|usr=}}
+
 
+
 
+
'''Ivermectin'''
+
{{tp|p=32330482|t=ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an  FDA warning, two letters to the editor and the authors  responses |pdf=|usr=}}
+
 
+
'''Various Leads'''
+
*[https://theconversation.com/we-found-and-tested-47-old-drugs-that-might-treat-the-coronavirus-results-show-promising-leads-and-a-whole-new-way-to-fight-covid-19-136789 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone]
+
*[https://doi.org/10.1038/s41586-020-2286-9 paper in nature]
+
{{tp|p=32251767|t=2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro |pdf=|usr=}}
+
 
+
 
+
'''Interferons'''
+
{{tp|p=32275914|t=2020. Type 1 interferons as a potential treatment against COVID-19 |pdf=|usr=}}
+
{{tp|p=32360182|t=2020. Antiviral activities of type I interferons to SARS-CoV-2 infection |pdf=|usr=}}
+
 
+
'''Plasmapheresis'''
+
 
+
'''Reconvalescent sera'''
+
{{tp|p=32243945|t=ä. Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection |pdf=|usr=}}
+
 
+
'''Therapeutic antibodies (virus-targeted)'''
+
*[https://www.foxnews.com/science/man-made-antibody-neutralizes-coronavirus-first-time anti covid mab]
+
*[https://www.telegraaf.nl/nieuws/750205601/nederlands-antilichaam-47-d11-blokkeert-infectie-coronavirus acmab 47d11]
+
{{tp|p=32375025|t=ä. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain  Camelid Antibodies |pdf=|usr=}}
+
 
+
'''Therapeutic antibodies and biologicals (cytokine/sugnal transduction)'''
+
{{tp|p=32247642|t=ä. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report |pdf=|usr=}}
+
{{tp|p=32241793|t=2020. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies |pdf=|usr=}}
+
{{tp|p=32243501|t=2020. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab |pdf=|usr=}}
+
{{tp|p=32343968|t=ä. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report |pdf=|usr=}}
+
 
+
'''Glucocorticoids'''
+
 
+
{{tp|p=32149773|t=ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial |pdf=|usr=}}
+
 
+
'''CRISPR genome editing technology'''
+
{{tp|p=32353252|t=ä. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza |pdf=|usr=}}
+
 
+
'''Virus interference'''
+
{{tp|p=32071427|t=2020. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses |pdf=|usr=}}
+
 
+
'''Other antirheumatic compounds'''
+
 
+
''Hydroxy-Chloroquine''
+
 
+
*check retina status; monitor rhythm known toxicity
+
*[https://justthenews.com/politics-policy/coronavirus/doctors-find-hydroxychloroquin-success-rate-91-urge-arizona-maybe-make 91% benefit]
+
*[https://www.themoscowtimes.com/2020/04/17/russia-approves-unproven-malaria-drug-to-treat-coronavirus-a70025 approval russia]
+
*[https://m.timesofindia.com/business/india-business/covid-19-68-new-companies-get-fdca-permit-to-make-hcq/amp_articleshow/75566317.cms scale up production]
+
*[https://www.medrxiv.org/content/10.1101/2020.04.26.20081059v1.full.pdf+html on safety, trial]
+
*[https://www.nejm.org/doi/full/10.1056/NEJMoa2012410?query=C19&cid=DM91569_NEJM_Registered_Users_and_InActive&bid=193180241 Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19] ''substance is useless.''
+
{{tp|p=32232419|t=ä. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know |pdf=|usr=}}
+
{{tp|p=32227189|t=ä. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 |pdf=|usr=}}
+
{{tp|p=32147496|t=2020. Of chloroquine and COVID-19 |pdf=|usr=}}
+
{{tp|p=32074550|t=2020. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies |pdf=|usr=}}
+
{{tp|p=32321905|t=2020. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database |pdf=|usr=}}
+
{{tp|p=32281583|t=2020. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32265182|t=2020. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review |pdf=|usr=}}
+
{{tp|p=32194981|t=2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro |pdf=|usr=}}
+
 
+
'''Chemoprevention Covid19'''
+
 
+
'''Antiviral agents Covid19'''
+
{{tp|p=32231345|t=2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high  capacity to mediate membrane fusion |pdf=|usr=}}
+
 
+
'''Lung regeneration and repair after Covid19'''
+
 
+
'''resilience enhancement'''
+
{{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
+
{{tp|p=32311498|t=ä. The impact of nutrition on COVID-19 susceptibility and long-term consequences |pdf=|usr=}}
+
{{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency  and Similar Future Global Health Threats |pdf=|usr=}}
+
 
+
'''psychoneuroimmunology'''
+
{{tp|p=32234338|t=ä. Using psychoneuroimmunity against COVID-19 |pdf=|usr=}}
+
 
+
'''cannabinoids'''
+
{{tp|p=32360437|t=ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?|pdf=|usr=}}
+
 
+
 
+
'''Complementary & Traditional chinese medicine & Ethnopharm'''
+
{{tp|p=32245701|t=ä. Is traditional Chinese medicine useful in the treatment of COVID-19?|pdf=|usr=}}
+
{{tp|p=32233641|t=2020. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19 |pdf=|usr=}}
+
*[https://www.aa.com.tr/en/africa/madagascar-slams-who-for-not-endorsing-its-herbal-cure/1836905 madagascar herbs]
+
{{tp|p=32229706|t=2020. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?|pdf=|usr=}}
+
{{tp|p=32037389|t=2020. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment |pdf=|usr=}}
+
{{tp|p=32334064|t=ä. Ayurveda and COVID-19: where psychoneuroimmunology and the meaning response meet |pdf=|usr=}}
+
{{tp|p=32361935|t=ä. Traditional Chinese and Western Medicines Jointly Beat COVID-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32065348|t=ä. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs |pdf=|usr=}}
+
{{tp|p=32308732|t=2020. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China |pdf=|usr=}}
+
 
+
'''Exercise'''
+
{{tp|p=32311497|t=ä. The immunological case for staying active during the COVID-19 pandemic |pdf=|usr=}}
+
 
+
'''Topical agents''' opening up the world of nano...
+
*[https://www.dailymail.co.uk/sciencetech/article-8315269/Commercial-mouthwash-prevent-COVID-19-transmission-scientists-say.html on mouth rinses]
+
 
+
'''Anticoagulants'''
+
*[[Anticoagulant in covid19]]
+
 
+
'''Vaccination Covid19'''
+
{{tp|p=32105090|t=2020. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic |pdf=|usr=}}
+
*[https://patch.com/massachusetts/cambridge/ma-company-takes-critical-step-toward-covid-19-vaccine mrna-1273, moderna]
+
 
+
{{tp|p=32183941|t=2020. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for  Immune Responses to SARS-CoV-2 |pdf=|usr=}}
+
----
+
 
+
 
+
{{tp|p=32371558|t=2020. Hydroxychloroquine use in the COVID-19 patient |pdf=|usr=}}
+
{{tp|p=32272008|t=2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32337664|t=ä. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia |pdf=|usr=}}
+
{{tp|p=32359035|t=2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 |pdf=|usr=}}
+
{{tp|p=32272196|t=2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology |pdf=|usr=}}
+
{{tp|p=32247038|t=2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 |pdf=|usr=}}
+
{{tp|p=32222466|t=2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China |pdf=|usr=}}
+
{{tp|p=32360516|t=ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |pdf=|usr=}}
+
{{tp|p=32353634|t=2020. COVID-19: Immunology and treatment options |pdf=|usr=}}
+
{{tp|p=32335290|t=2020. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection |pdf=|usr=}}
+
{{tp|p=32150618|t=ä. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) |pdf=|usr=}}
+
{{tp|p=32211771|t=ä. Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?|pdf=|usr=}}
+
{{tp|p=32211764|t=ä. Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019?|pdf=|usr=}}
+
{{tp|p=32266375|t=ä. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality |pdf=|usr=}}
+
{{tp|p=32255489|t=ä. Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients |pdf=|usr=}}
+
{{tp|p=32301957|t=ä. Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32344167|t=ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study |pdf=|usr=}}
+
{{tp|p=32305181|t=ä. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32360083|t=ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients |pdf=|usr=}}
+
{{tp|p=32306288|t=ä. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties |pdf=|usr=}}
+
{{tp|p=32277367|t=ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets |pdf=|usr=}}
+
{{tp|p=32373721|t=2020. Low dose lung radiotherapy for COVID-19 pneumonia  The rationale for a cost-effective anti-inflammatory treatment |pdf=|usr=}}
+
{{tp|p=32269021|t=2020. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32209231|t=2020. Computers and viral diseases  Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus |pdf=|usr=}}
+
{{tp|p=32264963|t=2020. A new clinical trial to test high-dose vitamin C in patients with COVID-19 |pdf=|usr=}}
+
{{tp|p=32280433|t=ä. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model |pdf=|usr=}}
+
{{tp|p=32345336|t=2020. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32351851|t=ä. A Coronavirus Disease 2019 (COVID-19) Patient with Multifocal Pneumonia Treated with Hydroxychloroquine |pdf=|usr=}}
+
{{tp|p=32241301|t=2020. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 |pdf=|usr=}}
+
{{tp|p=32226695|t=ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32318324|t=ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival |pdf=|usr=}}
+
{{tp|p=32340837|t=ä. Hydroxychloroquine in Covid-19: Does the end justify the means?|pdf=|usr=}}
+
{{tp|p=32219057|t=ä. The SARS-CoV-2 Vaccine Pipeline: an Overview |pdf=|usr=}}
+
{{tp|p=32360420|t=ä. Cytokine storm intervention in the early stages of COVID-19 pneumonia |pdf=|usr=}}
+
 
+
{{tp|p=32337328|t=2020. Coronaviruses: A patent dataset report for research and development (R&D) analysis |pdf=|usr=}}
+
{{tp|p=32247211|t=2020. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to  India and other developing countries |pdf=|usr=}}
+
{{tp|p=32335366|t=2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis |pdf=|usr=}}
+
{{tp|p=32333972|t=ä. Letter to the Editor in response to the article ?COVID-19 and diabetes: Can DPP4  inhibition play a role?? |pdf=|usr=}}
+
{{tp|p=32333966|t=2020. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications |pdf=|usr=}}
+
{{tp|p=32333969|t=ä. Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? ? GLP-1 Might Play One Too |pdf=|usr=}}
+
{{tp|p=32283128|t=ä. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?|pdf=|usr=}} ''on ace2 via adam17, nfkb via dpp4''
+
{{tp|p=32309622|t=ä. Emerging Therapeutic Strategies for COVID-19 patients |pdf=|usr=}}
+
{{tp|p=32336723|t=2020. Treatment of SARS-CoV-2: How far have we reached?|pdf=|usr=}}
+
{{tp|p=32321878|t=2020. Is GSK3beta a molecular target of chloroquine treatment against COVID-19?|pdf=|usr=}}
+
{{tp|p=32378648|t=2020. Rapid review for the anti-coronavirus effect of remdesivir |pdf=|usr=}}
+
{{tp|p=32378647|t=2020. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that  far?|pdf=|usr=}}
+
{{tp|p=32147628|t=2020. Discovering drugs to treat coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32371138|t=ä. Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19 |pdf=|usr=}}
+
{{tp|p=32198066|t=ä. Advance of promising targets and agents against COVID-19 in China |pdf=|usr=}}
+
{{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
+
{{tp|p=32320852|t=ä. Deja vu: Stimulating open drug discovery for SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32304645|t=ä. Boosting the arsenal against COVID-19 through computational drug repurposing |pdf=|usr=}}
+
{{tp|p=32266694|t=ä. Chloroquine for COVID-19 Infection |pdf=|usr=}}
+
{{tp|p=32373183|t=2020. Chloroquine and hydroxychloroquine in the context of COVID-19 |pdf=|usr=}}
+
{{tp|p=32343658|t=2020. Medication for COVID-19-an Overview of Approaches Currently Under Study |pdf=|usr=}}
+
{{tp|p=32344202|t=2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy  and vaccine development |pdf=|usr=}}
+
{{tp|p=32249203|t=ä. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and  rapid translational development |pdf=|usr=}}
+
 
+
{{tp|p=32379923|t=2020. Is BCG vaccination causally related to reduced COVID-19 mortality?|pdf=|usr=}}
+
{{tp|p=32333818|t=2020. COVID-19: lambda interferon against viral load and hyperinflammation |pdf=|usr=}}
+
{{tp|p=32338155|t=2020. Rheumotologitsts  view on the use of hydroxychloroquine to treat COVID-19 |pdf=|usr=}}
+
{{tp|p=32228222|t=2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension |pdf=|usr=}}
+
{{tp|p=32148172|t=2020. Timely development of vaccines against SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=C7118608|t=ä. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System |pdf=|usr=}}
+
{{tp|p=32065055|t=2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody |pdf=|usr=}}
+
{{tp|p=32346491|t=ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study |pdf=|usr=}}
+
{{tp|p=32292627|t=ä. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment |pdf=|usr=}}
+
 
+
{{tp|p=32363880|t=2020. Medical treatment options for COVID-19 |pdf=|usr=}}
+
{{tp|p=32372695|t=2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol |pdf=|usr=}}
+
{{tp|p=32347925|t=ä. Statin therapy in COVID-19 infection |pdf=|usr=}}
+
{{tp|p=32347923|t=ä. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety |pdf=|usr=}}
+
{{tp|p=32337546|t=ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?|pdf=|usr=}}
+
{{tp|p=32282032|t=ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients |pdf=|usr=}}
+
{{tp|p=32285293|t=ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV |pdf=|usr=}}
+
{{tp|p=C7129866|t=ä. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19 |pdf=|usr=}}
+
{{tp|p=32341100|t=2020. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective |pdf=|usr=}}
+
{{tp|p=32265310|t=ä. Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19 |pdf=|usr=}}
+
{{tp|p=32271462|t=2020. Inositol and pulmonary function  Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?|pdf=|usr=}}
+
{{tp|p=32271456|t=2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease  2019 |pdf=|usr=}}
+
{{tp|p=32271454|t=2020. Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19 |pdf=|usr=}}
+
{{tp|p=32329881|t=2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience |pdf=|usr=}}
+
{{tp|p=32329879|t=2020. (Naturlal products: )An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections |pdf=|usr=}}
+
{{tp|p=32327396|t=ä. COVID-19 and Bacillus Calmette-Guerin: What is the Link?|pdf=|usr=}}
+
{{tp|p=32279655|t=2020. Can Hepatitis A Vaccine Provide Protection Against COVID-19?|pdf=|usr=}}
+
{{tp|p=32250170|t=2020. Will plant-made biopharmaceuticals play a role in the fight against COVID-19?|pdf=|usr=}}
+
{{tp|p=32329380|t=2020. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia |pdf=|usr=}}
+
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
+
{{tp|p=32117569|t=2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China |pdf=|usr=}}
+
{{tp|p=32212513|t=2020. The Trial of Chloroquine in the Treatment of Corona Virus Disease 2019 COVID-19 and Its Research Progress in Forensic Toxicology |pdf=|usr=}}
+
{{tp|p=32269766|t=2020. In silico identification of vaccine targets for 2019-nCoV |pdf=|usr=}}
+
 
+
{{tp|p=32374074|t=2020. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease |pdf=|usr=}}
+
{{tp|p=32265848|t=2020. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses |pdf=|usr=}}
+
{{tp|p=32363145|t=ä. An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19)  patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine |pdf=|usr=}}
+
{{tp|p=32363144|t=ä. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin |pdf=|usr=}}
+
*'''[[Biophysics of aerosols]]'''
+
*'''[[Other routes of infection]]'''
+
{{tp|p=32247692|t=ä. Faecal-oral transmission of SARS-COV-2: practical implications |pdf=|usr=}}
+
{{tp|p=32367287|t=ä. New evidence of SARS-CoV-2 transmission through the ocular surface |pdf=|usr=}}
+
{{tp|p=32363144|t=ä. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin |pdf=|usr=}}
+
{{tp|p=32251729|t=ä. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design |pdf=|usr=}}
+
{{tp|p=32313872|t=ä. COVID-19 convalescent plasma transfusion |pdf=|usr=}}
+
{{tp|p=32251365|t=ä. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy |pdf=|usr=}}
+
{{tp|p=32375153|t=2020. HMGB1: A Possible Crucial Therapeutic Target for COVID-19?|pdf=|usr=}}
+
{{tp|p=32186952|t=2020. COVID-19, an emerging coronavirus infection: advances and prospects in designing  and developing vaccines, immunotherapeutics, and therapeutics |pdf=|usr=}}
+
{{tp|p=32341910|t=2020. SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis |pdf=|usr=}}
+
{{tp|p=32300370|t=2020. Can an effective SARS-CoV-2 vaccine be developed for the older population?|pdf=|usr=}}
+
{{tp|p=32259480|t=ä. SARS-CoV-2 Vaccines: Status Report |pdf=|usr=}}
+
{{tp|p=32362644|t=2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use |pdf=|usr=}}
+
{{tp|p=32317408|t=2020. Perspectives for repurposing drugs for the coronavirus disease 2019 |pdf=|usr=}}
+
{{tp|p=32317405|t=2020. Tracking the impact of interventions against COVID-19 in absence of extensive testing |pdf=|usr=}}
+
{{tp|p=32201449|t=2020. Drug targets for corona virus: A systematic review |pdf=|usr=}}
+
{{tp|p=32278018|t=ä. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society |pdf=|usr=}}
+
{{tp|p=32366728|t=2020. Medical Education During the COVID-19 Pandemic: A Single Institution Experience |pdf=|usr=}}
+
{{tp|p=32366726|t=2020. Management of Asthma in Children during COVID-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32366725|t=2020. COVID -19 Pandemic: The Challenges for Pediatric Oncology |pdf=|usr=}}
+
{{tp|p=32358227|t=2020. Demystifying BCG Vaccine and COVID-19 Relationship |pdf=|usr=}}
+
{{tp|p=32291382|t=2020. Coronavirus Vaccines: Light at the End of the Tunnel |pdf=|usr=}}
+
{{tp|p=32238614|t=2020. Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak |pdf=|usr=}}
+
{{tp|p=32321620|t=ä. Corticosteroid use for 2019-nCoV infection: A double-edged sword |pdf=|usr=}}
+
{{tp|p=32341599|t=2020. Is Immuno-modulation the Key to COVID-19 Pandemic?|pdf=|usr=}}
+
 
+
{{tp|p=32320825|t=ä. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status |pdf=|usr=}}
+
{{tp|p=32328406|t=ä. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains |pdf=|usr=}}
+
{{tp|p=32335561|t=2020. Update on treatment of COVID-19: ongoing studies between promising and disappointing results |pdf=|usr=}}
+
{{tp|p=32335560|t=2020. Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials |pdf=|usr=}}
+
{{tp|p=32342098|t=ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib |pdf=|usr=}}
+
{{tp|p=32372149|t=ä. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?|pdf=|usr=}}
+
{{tp|p=32352026|t=2020. Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach |pdf=|usr=}}
+
{{tp|p=32272396|t=ä. The Possible of Immunotherapy for COVID-19: a Systematic Review |pdf=|usr=}}
+
{{tp|p=32311668|t=ä. SARS-Cov-2 infection: response of human immune system and possible implications for the rapid test and treatment |pdf=|usr=}}
+
{{tp|p=32234467|t=ä. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality |pdf=|usr=}}
+
{{tp|p=32234466|t=ä. Coronavirus disease 2019 (COVID-19): current status and future perspectives |pdf=|usr=}}
+
{{tp|p=32205204|t=ä. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial |pdf=|usr=}}
+
{{tp|p=32171740|t=ä. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?|pdf=|usr=}}
+
{{tp|p=32070753|t=2020. Chloroquine for the 2019 novel coronavirus SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32278811|t=ä. Drug repositioning is an alternative for the treatment of coronavirus COVID-19 |pdf=|usr=}}
+
{{tp|p=32259575|t=ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF  COVID 19 |pdf=|usr=}}
+
{{tp|p=32361028|t=ä. ?Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ? |pdf=|usr=}}
+
{{tp|p=32251732|t=ä. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage |pdf=|usr=}}
+
{{tp|p=32251731|t=ä. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32360231|t=ä. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?|pdf=|usr=}}
+
{{tp|p=32335281|t=ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19 |pdf=|usr=}}
+
{{tp|p=32305589|t=ä. Combating Devastating COVID -19 by Drug Repurposing |pdf=|usr=}}
+
{{tp|p=32305588|t=ä. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and  anti-IL-6 monoclonal antibodies |pdf=|usr=}}
+
{{tp|p=32298745|t=ä. Successful treatment of plasma exchange followed by intravenous immunogloblin in  a critically ill patient with 2019 novel coronavirus infection |pdf=|usr=}}
+
{{tp|p=C7152897|t=ä. Chloroquine as prophylactic agent against COVID-19?|pdf=|usr=}}
+
{{tp|p=32283177|t=ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in  SARS-CoV-2 Infections |pdf=|usr=}}
+
{{tp|p=32194152|t=ä. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine |pdf=|usr=}}
+
{{tp|p=32179150|t=ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?|pdf=|usr=}}
+
{{tp|p=32147516|t=ä. Arguments in favour of remdesivir for treating SARS-CoV-2 infections |pdf=|usr=}}
+
{{tp|p=32145363|t=2020. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 |pdf=|usr=}}
+
{{tp|p=32363157|t=2020. Chloroquine: Can it be a Novel Drug for COVID-19 |pdf=|usr=}}
+
{{tp|p=32226290|t=2020. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 |pdf=|usr=}}
+
{{tp|p=32226288|t=2020. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New  Coronavirus (SARS-CoV-2): A Review and Perspective |pdf=|usr=}}
+
{{tp|p=32226289|t=2020. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32300868|t=ä. Balneotherapy and human immune function in the era of COVID-19 |pdf=|usr=}}
+
{{tp|p=32321655|t=ä. An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients |pdf=|usr=}}
+
{{tp|p=32251768|t=2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |pdf=|usr=}}
+
 
+
*[https://www.infowars.com/experts-suggest-90-million-oxford-university-coronavirus-vaccine-doesnt-work/ Oxford vaccine failed in monkeys]
+
{{tp|p=32305009|t=ä. Investigating hypothiocyanite against SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32173576|t=2020. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression |pdf=|usr=}}
+
{{tp|p=32218340|t=2020. Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?|pdf=|usr=}}
+
{{tp|p=32354030|t=2020. Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work |pdf=|usr=}}
+
{{tp|p=32325767|t=2020. COVID-19 Drug Discovery Using Intensive Approaches |pdf=|usr=}}
+
{{tp|p=32353978|t=2020. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design |pdf=|usr=}}
+
 
+
{{tp|p=32368489|t=2020. The pathogenesis and alternative treatment of SARS-CoV2 |pdf=|usr=}}
+
{{tp|p=32289016|t=2020. Herbal medicine and pattern identification for treating COVID-19: a rapid review  of guidelines |pdf=|usr=}}
+
{{tp|p=32125455|t=ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target |pdf=|usr=}}
+
{{tp|p=32347443|t=ä. Camostat mesilate therapy for COVID-19 |pdf=|usr=}}
+
{{tp|p=32333086|t=ä. Remdesivir bei Patienten mit schwerer COVID-19 |pdf=|usr=}}
+
{{tp|p=32378817|t=2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients |pdf=|usr=}}
+
*[https://www.nature.com/articles/d41573-020-00073-5 Nature: The COVID-19 vaccine development landscape]
+
{{tp|p=32283237|t=ä. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?|pdf=|usr=}}
+
{{tp|p=32278797|t=ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32348818|t=ä. Risks of Hydroxychloroquine use for COVID-19 prophylaxis |pdf=|usr=}}
+
{{tp|p=32339701|t=ä. Potential role of Janus kinase inhibitors in COVID-19 |pdf=|usr=}}
+
{{tp|p=32344070|t=ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19 |pdf=|usr=}}
+
{{tp|p=32283236|t=ä. Does hydroxychloroquine combat COVID-19? A timeline of evidence |pdf=|usr=}}
+
 
+
{{tp|p=32330546|t=ä. Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated with Hydroxychloroquine and/or Azithromycin |pdf=|usr=}}
+
{{tp|p=32283123|t=ä. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus  Disease 2019) Treatment |pdf=|usr=}}
+
{{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
+
{{tp|p=32361744|t=ä. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease |pdf=|usr=}}
+
{{tp|p=32196083|t=ä. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression |pdf=|usr=}}
+
{{tp|p=32317220|t=ä. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 |pdf=|usr=}}
+
{{tp|p=32291137|t=ä. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?|pdf=|usr=}}
+
{{tp|p=32284326|t=2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency |pdf=|usr=}}
+
{{tp|p=32094225|t=2020. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase  from Middle East respiratory syndrome coronavirus |pdf=|usr=}}
+
{{tp|p=32295479|t=2020. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study |pdf=|usr=}}
+
{{tp|p=32306862|t=2020. Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes |pdf=|usr=}}
+
{{tp|p=32266873|t=2020. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2?-O-ribose methyltransferase |pdf=|usr=}}
+
{{tp|p=32238078|t=2020. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel |pdf=|usr=}}
+
 
+
{{tp|p=32374474|t=2020. Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells |pdf=|usr=}}
+
{{tp|p=32281268|t=2020. G6PD and chloroquine: Selecting the treatment against SARS?CoV?2?|pdf=|usr=}}
+
{{tp|p=32255648|t=ä. A Community Letter Regarding Sharing Biomolecular Simulation Data for COVID-19 |pdf=|usr=}}
+
{{tp|p=32315171|t=ä. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study |pdf=|usr=}}
+
{{tp|p=32243270|t=2020. Potential therapeutic agents against COVID-19: What we know so far |pdf=|usr=}}
+
{{tp|p=32254064|t=2020. Deployment of convalescent plasma for the prevention and treatment of COVID-19 |pdf=|usr=}}
+
{{tp|p=32352407|t=2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor  antagonists |pdf=|usr=}}
+
{{tp|p=32167489|t=ä. The convalescent sera option for containing COVID-19 |pdf=|usr=}}
+
{{tp|p=32326602|t=2020. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 |pdf=|usr=}}
+
{{tp|p=32326426|t=2020. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression |pdf=|usr=}}
+
 
+
{{tp|p=32353761|t=2020. Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review |pdf=|usr=}}
+
{{tp|p=32305026|t=ä. Challenges of Convalescent Plasma Therapy on COVID-19 |pdf=|usr=}}
+
{{tp|p=32314081|t=ä. Pharmacologic Therapy for COVID-19 Infection |pdf=|usr=}}
+
{{tp|p=32289152|t=2020. COVID-19 and emerging viral infections: The case for interferon lambda |pdf=|usr=}}
+
{{tp|p=32302401|t=2020. Targeting potential drivers of COVID-19: Neutrophil extracellular traps |pdf=|usr=}}
+
{{tp|p=32359878|t=2020. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32171450|t=2020. Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus |pdf=|usr=}}
+
{{tp|p=32173287|t=ä. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines |pdf=|usr=}}
+
{{tp|p=32373322|t=ä. Fighting COVID-19 with water |pdf=|usr=}}''dehydration of mucous glycans''
+
{{tp|p=32372051|t=ä. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2 |pdf=|usr=}}
+
{{tp|p=32335161|t=ä. In the search of potential epitopes for Wuhan seafood market pneumonia virus using high order nullomers |pdf=|usr=}}
+
{{tp|p=32300051|t=2020. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement  on access to IL-6-targeting therapies for COVID-19 |pdf=|usr=}}
+
{{tp|p=32171872|t=ä. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study |pdf=|usr=}}
+
{{tp|p=32333918|t=ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact |pdf=|usr=}}
+
{{tp|p=32283153|t=ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1 |pdf=|usr=}}
+
{{tp|p=32362440|t=ä. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases |pdf=|usr=}}
+
{{tp|p=32232474|t=ä. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure |pdf=|usr=}}
+
{{tp|p=32348485|t=ä. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19  Patients |pdf=|usr=}}
+
{{tp|p=32348489|t=ä. COVID-19: Is Everything Appropriate to Create an Effective Vaccine?|pdf=|usr=}}
+
 
+
{{tp|p=32293807|t=2020. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID?19: initial assessment |pdf=|usr=}}
+
{{tp|p=32307268|t=2020. Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC?MSE analysis |pdf=|usr=}}
+
{{tp|p=32122812|t=2020. Traditional Chinese medicine is a resource for drug discovery against 2019 novel  coronavirus (SARS-CoV-2) |pdf=|usr=}}
+
{{tp|p=32113846|t=ä. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus |pdf=|usr=}}
+
{{tp|p=32080993|t=2020. The Author s Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for  the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR |pdf=|usr=}}
+
{{tp|p=32080992|t=2020. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission  of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for  the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR |pdf=|usr=}}
+
{{tp|p=32056407|t=2020. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR |pdf=|usr=}}
+
{{tp|p=32281317|t=2020. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea |pdf=|usr=}}
+
{{tp|p=32356252|t=ä. COVID-19: Therapeutics and Their Toxicities |pdf=|usr=}}
+
{{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
+
{{tp|p=32052466|t=2020. Potential interventions for novel coronavirus in China: A systematic review |pdf=|usr=}}
+
{{tp|p=32022276|t=2020. Immunoinformatics?aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019?nCoV |pdf=|usr=}}
+
{{ttp|p=32249185|t=ä. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection |pdf=|usr=}}
+
{{ttp|p=32205092|t=ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |pdf=|usr=}}
+
*[https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds on ivermectin]
+

Aktuelle Version vom 21. September 2021, 06:15 Uhr

homepage
hottest actual papers
 P further streaming-in related content is here
 CHERRYPICKING STUDIES IS NOT SCIENCE
Reviews on covid drug development


PHA related options:


A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
=======================================================================================
COVID19 is now a CURABLE disease !!!
=======================================================================================

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis